CURRICULUM VITAE

**Name** John D. Roberts, MD

**Education and Training**

09/1968-06/1972 Harvard University, AB (Social Studies)

08/1972-05/1976 University of Pennsylvania, MD

07/1976-06/1980 Resident, Internal Medicine and Pediatrics, University of North Carolina at Chapel Hill

07/1982-06/1984 Fellow, Medical Oncology, University of Vermont

07/2011-05/2012 Trainee in Hospice and Palliative Care

**Employment and Academic Appointments**

**Medical Practice**

10/1980-04/82

**University of Vermont**

07/1984-06/1990 Assistant Professor, Internal Medicine (Hematology/Oncology)

07/1990-06/1993 Associate Professor (with tenure), Internal Medicine (Hematology/Oncology)

07/1986-06/1993 Faculty, Pharmacology (secondary appointment)

07/1986-06/1993 Graduate Faculty

07/1991-06/1993 Faculty, Program in Cellular and Molecular Pharmacology

**Virginia Commonwealth University**

07/1993-06/2002 Associate Professor, Internal Medicine (Hematology/Oncology)

07/2002-06/2004 Professor, Internal Medicine (Hematology, Oncology & Palliative Care)

07/2004-06/2012 Professor (with tenure), Internal Medicine (Hematology, Oncology & Palliative Care)

07/2006-06/2012 Graduate Faculty

01/2007-06/2012 Faculty, Pharmaceutics (secondary appointment)

**Yale University**

07/2012-06/2021 Professor, Internal Medicine (Medical Oncology)

07/2021- Professor, Internal Medicine (Hematology)

**Administrative Positions**

**University of Vermont**

**Vermont Cancer Center (NCI-designated)**

07/1990-06/1993 Associate Director for Clinical Research

07/1991-06/1993 Program Leader, Clinical Research

07/1991-06/1993 Director, Data Management Facility

**Medical Center**

07/1992-06/1993 Acting Director, Medical Oncology Fellowship Program

**Virginia Commonwealth University**

**Medical Center**

07/1995-06/1997 Interim Director, Virginia Sickle Cell Awareness Program

**Health System**

07/2006-06/2012 Co-Director, Adult Sickle Cell Program

07/2008-06/2012 Interim Medical Director, Oncology Service Line

07/1993-06/2004 Medical Director, Urological Tumor Center

**Massey Cancer Center (NCI-designated)**

07/1996-06/2012 Associate Director for Clinical Research

07/1996-06/2012 Director, Clinical Research Shared Resource

07/1996-06/2011 Program Co-Leader, Molecular Cancer Therapeutics

**Department of Medicine**

07/2008-06/2011 Interim Chair, Division of Hematology, Oncology & Palliative Care

**Yale University**

**Yale New Haven Health**

07/2012-04/2022 Medical Director, Adult Sickle Cell Program

**Yale Cancer Center**

09/2012-05/2013 Assistant Director, Clinical Trials Office

**University/Medical Center Committees**

**University of Vermont**

**School of Medicine**

1991 Member, Department of Pathology Chair Search Committee

**Vermont Cancer Center**

07/1991-06/1993 Member, Executive Committee

07/1987-06/1992 Member, Speaker's Committee

07/1986-06/1993 Member, Lake Champlain Cancer Research Organization Advisory Committee

**Fletcher Allen Medical Center**

07/1988-06/1993 Member, Cancer Committee

07/1985-06/1989 Member, General Clinical Research Center Advisory Committee

**Virginia Commonwealth University**

**University**

07/1994-12/1999 Member, IRB

07/1994-06/1995 Member, Conflict of Interest Policy Task Force

12/1999-12/2000 Member, IRB Task Force

05/2000-06/2011 Vice-Chair, IRB Panel A

06/2011-05/2012 Chair, IRB Panel A

**Medical Center**

07/1995-12/1995 Chair, Director for Sickle Cell Services Search Committee

07/1995-04/1997 Member, Massey Cancer Center Director Search

07/1995-06/2010 Member, General Clinical Research Center Advisory

07/2006-05/2007 Member, Molecular Imaging Directory Search Committee

07/2010-05/2012 Member, Clinical and Translational Research Center Advisory Committee

07/2011-05/2012 Member, Clinical and Translational Research Center Academy of Mentors

**Health System**

07/1993-06/2012 Member, Clinical Oncology Services Executive Committee

**Massey Cancer Center**

07/1996-05/2012 Member, Protocol Review and Monitoring Committee

**Department of Medicine**

07/2006-06/2009 Member, Promotion and Tenure Committee

**Division of Hematology, Oncology & Palliative Care**

07/2008-05/2012 Member, Fellowship Committee

**Yale University**

**University**

10/2012-12/2016, Co-Chair, HIC I (IRB Panel Cancer)

01/2017-12/2017, Executive Chair, Yale IRBs

01/2017-08/2018, Chair, HIC IB (IRB Cancer Panel)

**Yale Cancer Center**

07/2012-06/2016 Member, Data and Safety Monitoring Committee

02/2015-04/2017 Member, CTO Strategic Planning Committee

02/2018-06/2019, Member, Data and Safety Monitoring Committee

**Section of Medical Oncology**

05/2013-05/2015 Member, Fellowship Committee

**Connecticut Hospital for Special Care**

07/2012-06/2019, CT Sickle Cell Disease Consortium Stakeholders

**Yale New Haven Health**

07/2019-02/21 Physician Member, Clinical Redesign

03/2021-06/22 Physician Member, Care Signature

**Board Certification**

10/1980 American Board of Internal Medicine\*

04/1982 American Board of Pediatrics\*

10/1984 American Board of Internal Medicine, Medical Oncology\*

10/2012 American Board of Internal Medicine, Hospice and Palliative Care#

\* Re-certification not required

#Re-certification ongoing through ABIM Longitudinal Assessment Program  
  
**Professional Honors & Recognition**

06/1972 Harvard University, AB, Magna Cum Laude

06/2004 Fellows Appreciation Award, VCU Division of Hematology, Oncology & Palliative Care

04/2008 Alpha Omega Alpha

09/2012 NCI Harry Hines Award (Community Clinical Oncology Program Principal Investigator of the Year)

03/2015 Best Presentation, Yale-MIT CBIT-CORE Hackathon

06/2018 Yale Fellows Award for Teaching and Mentoring in Hematology

**Peer-Reviewed Grants:**

**Past**

NIH/NCI

P30-CA16059

Massey Cancer Center Support Grant: Senior Leader, Program Leader, Shared Resource Director

PI: Gordon Ginder, MD

Percent Effort: ~30%

Period: 7/1/1993-5/30/2012

NIH/NCI

U10-CA52784

VCU Minority Based Clinical Community Oncology Program

PI: John D Roberts, MD

Percent Effort: ~20%

Period: 7/1/1995-05/30/2012

NIH/NCI

N01-CM-62208 (subcontract)

Southeast Phase II Consortium

PI: Daniel Sullivan, MD (VCU Subcontractor: John D Roberts, MD)

Percent Effort: ~5%

Period: 01/2006-05/2012

NIH/NCI

RC2-CA1431-01

Proteasome/HDAC inhibition in leukemia/MDS: Phase I trial and correlative studies

PI: Steven Grant, MD

Percent Effort: ~5%

Period: 12/2009-11/2011

NIH

RAID for 5-hydroxymethylfuran in sickle cell disease

PI: John D Roberts, MD

Percent Effort: none (materials only)

Period: 7/1/07-3/31/11

NIH/NHLBI

1U10-HL083732

VCU Sickle Cell Disease Research Network

PI: Wally Smith

Percent Effort: ~5%

04/17/2006 – 03/31/2011

V Foundation

Re-establishing the leukemia cell death program with sorafenib and bcl-2 antagonists

PI: Steven Grant, MD

Percent Effort: ~5%

11/01/2007 – 10/31/2010

NIH/NCI

R21-CA115260

CDK inhibitors with histone deacetylase inhibitors in acute leukemia

PI: Steven Grant, MD

Percent Effort: ~5%

06/01/2005 to 05/31/2008

NIH/NCI

R21-CA110953

Flavopiridol and bortezomib in myeloma and B-cell neoplasms

PI: Steven Grant, MD  
Percent Effort: ~4%

06/15/2004 to 05/31/2008

NIH/NCI

R21-CA106139

Flavopiridol and imatinib in bcr/abl+ leukemia

PI: Steven Grant, MD

Percent Effort: ~5%

10/ 01/2003 – 9/30/2005

NIH/NCI

R25-CA093423

Pre- and post-doctoral training in cancer control

PI: Hermine Maes, PhD

Percent Effort: none (Mentor)

09/01/2002 – 08/31/2008

V Foundation

Combined proteosome and cyclin dependent kinase inhibition: a novel therapeutic strategic in hematologic malignancies

PI: Steven Grant, MD

Percent Effort: ~5%

10/01/2003 to 09/30/2006

NIH/NHLBI

R01-HL64122

Pain in sickle cell epidemiology study

PI: Wally Smith, MD

Percent Effort: ~4%

07/2001-06/2004

NIH/NCI

U10-CA76642

Phase I studies of anticancer drug and gene therapy

PI: Franco Muggia, MD

Percent Effort: ~1%

07/2000-06/2001

NIH/NCI

R21-CA85562

Phase Ia/Ib trial of modulation of the biological response to interleukin-2 with bryostatin 1

PI: John D Roberts, MD

Percent Effort: ~10%

07/2000-06/2003

NIH/NCI

R03-CA7741

Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent non-Hodgkin’s lymphoma

PI: Steven Grant, MD

Percent Effort: ~5%

07/1998-06/2001

NIH/NCI

R21-CA66740

Phase I study: Adoptive cellular therapy with bryostatin

PI: Harry D Bear, MD, PhD

Percent Effort: ~10%

07/1995-06/1997

NIH/NCI

R03-CA66990

Phase IB study of bryostatin 1

PI: Steven Grant, MD

Percent Effort: ~5%

07/1995-06/1997

FDA

000948

Vanillin for sickle cell disease

PI: Paul Swerdlow, MD, PhD

Percent Effort: ~1%

07/1995-06/1998

NIH

N01-CM57237

Master agreement for study of biological response modifiers

PI: Harry D Bear, MD, PhD

Percent Effort: (none)

07/1994-06/1997

NIH/NCI

Vermont Cancer Center affiliation with the Eastern Cooperative Oncology Group

PI: John D Roberts, MD

Percent Effort: ~10%

07/1991-06/1993

NIH/NCI

P30-CA22435

Vermont Cancer Center Support Grant: Program Leader, Shared Resource Director

PI: Roger Foster, MD

Percent Effort: ~20%

07/1991-06/1993

American Cancer Society

CH-494

Cellular pharmacology of bis(platinum) complexes

PI: John D Roberts, MD

Percent Effort: ~30%

07/1990-06/1994

NIH/NCI

K08-CA01143

Clinical Investigator Career Development Award: Pharmacology of novel platinum complexes

PI: John D Roberts, MD

Percent Effort: ~75%

07/1987-06/1990

American Cancer Society

Clinical Oncology Career Development Award: Pharmacology of novel platinum complexes

PI: John D Roberts, MD

Percent Effort: ~75%

07/1987-06/1988

NIH

Equipment Grant

Co-Investigator

05/1987

American Cancer Society, Vermont Chapter

Principal Investigator: Pharmacology of novel platinum complexes

PI: John D Roberts, MD

Percent Effort: none

07/1985-06/1986

**Grants (not peer reviewed) & Contracts (Principal Investigator)**

Community Health Network of Connecticut

Consultant

11/2015-12/2021

Millennium Pharmaceuticals, Inc

CZOL4446EUS130

Phase I trial of dacarbazine and bortezomib in melanoma and soft tissue sarcoma

PI: John D Roberts, MD

Percent Effort: ~1%

07/2004 –06/2011

NSABP Foundation

TIND-415

Master Purchased Services Agreement

PI: John D Roberts, MD

Percent Effort ~1%

02/01/2001 – 11/30/2010

Novartis Pharmaceuticals Corporation

Pilot/phase I study of zoledronic acid in sickle cell disease

PI: John D Roberts, MD

Percent Effort: ~1%

07/02/2007 – 03/30/2008

Chiron Corporation

High dose interleukin-2 therapy in “lymphodepleted primed” patients with metastatic melanoma

Site PI: John D Roberts, MD

Percent Effort: ~1%

09/07/2005 to 08/31/2006

Chiron Corporation

Laboratory correlative studies of phase I trials using interleukin-2

PI: John D Roberts, MD

Percent Effort: ~1%

07/2000-06/2003

**Contracts (Site Principal Investigator)**

Selexys

A phase II, multicenter, randomized, placebo-controlled, double-blind, 12-month study to assess safety and efficacy of SelG1 with or without hydroxyurea therapy in sickle cell disease patients with sickle related pain crises.

05/2014 – 10/2014

Novuspharma

Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer after one prior chemotherapy regimen

07/2001-06/2002

Novartis

Phase I open label study of the combination of Gleevec (STI571) with cisplatin and etoposide for previously untreated extensive stage small cell lung cancer

07/2001-06/2002

Lilly

A phase I dose-escalating study of LY231514 and docetaxel administered every 21 days in patients with locally advanced or metastatic cancer

07/1998-06/2000

Agouron, Inc

Phase I study of AG2034

07/1996-06/1998

Taiho

Phase III study of UFT v 5-FU in colorectal cancer

07/1996-12/1996

Virginia Department of Health

Medical Director, Virginia Sickle Cell Awareness Program

07/1995-06/1997

DuPont Merck

Phase II trial of DUP 941 in prostate cancer

07/1994-06/1995

Genetics Institute

Phase II clinical trial of C9416-14 in breast cancer

07/1994-06/1996

Berlex

Phase II/III clinical trial of BL07-3113 in breast cancer

07/1994-12/1994

Syntex Research

Phase I/II clinical trial of RS-25259

07/1994-12/2004

Zeneca

Phase III clinical trial ZD1694 in advanced colorectal cancer

07/1993-06/1996

Genentech

Phase III clinical trial 10510g in breast cancer

07/1993-06/1995

DuPont Merck

Clinical trial of DuP 941 in breast cancer

07/1991-06/1993

DuPont Merck

Clinical Trial in DuP 937 prostate cancer

07/1992-06/1993

MGI

Phase II trial of DDTI with cisplatin in lung cancer

07/1990-06/1991

**Contracts (Site Co-Investigator)**

Lilly

Phase I study of leucovoran/5-fluorouracil/gemcitabine

07/1996-06/1999

Allos

Phase I trial of RSR13

07/1995-06/1997

**Consultation**

10/2014-12/2022 Community Health Network of Connecticut

01/2017-current Verimed Health Analytics

02-2020-current Pfizer

04-2022-2023 NE Nutrients

# Invited Lectures:

11/6-8/2019 Co-Founder and Co-Director, 1st Annual American Society for Hematology Sickle Cell Disease Centers Workshop

08/28/2019 NHLBI

Moderator, Sickle Cell Adult Providers Network Mini-Symposium

NHLBI Annual Sickle Cell Research Meeting

04/10/2019 American College of Physicians Annual Meeting

Invited Speaker: Inpatient sickle cell disease care: Managing our inpatients to keep them outpatients

10/17/18 Westchester Medical Center

Update in sickle cell disease

05/02/2015 American College of Physicians Annual Meeting

Invited Speaker: Inpatient care of the patient with sickle cell: A case-based approach

09/27/2011 NCI

Annual CCOP Meeting

What is “research” in clinical research and who should pay for it?

09/19/2011 Yale University

Hematology-Oncology Grand Rounds

The VCU Adult Sickle Cell Program: service and research

08/17/2010 University of Vermont

Hematology-Oncology Grand Rounds

A new phase II trial design for the era of targeted agents

11/10/2008 Moffitt Cancer Center Total Cancer Care Conference

Puerto Rico, USA

A new phase II trial design for the era of targeted agents

01/12/2008 Southeast Phase II Consortium

1st Annual Meeting

A new approach to phase II trials

03/10/2003 CTEP Early Drug Development Meeting

Phase Ib trial of bryostatin and interleukin-2 in melanoma and renal cell cancer

01/12/1998. University of North Carolina at Chapel Hill

Phase I trial of lometrexol

05/22/1993 AACR Annual Meeting

Co-Chair, Mini-symposium, Platinum complexes: Clinical and related

Studies

02/13/1993 Virginia Commonwealth University

Hematology-Oncology Grand Grounds

Aspects of developmental therapeutics at the Vermont Cancer Center

02/3/1992 University of Iowa

Hematology-Oncology Grand Rounds

Aspects of developmental therapeutics at the Vermont Cancer Center

**Graduate Students**

07/2018-06/2020 Thesis Mentor (PhD, Investigative Medicine) Susanna Curtis, MD

09/2018-05/2019 Thesis Mentor (Physician’s Assistant) Ms. Emily Jimenez

09/2013-05/2014 Thesis Mentor (Physician’s Assistant) Ms. Meredith Keppel

07/2010-04/2012 PhD Dissertation Committee (Biostatistics) Ms. E Sheldon

07/2008-04/2010 PhD Dissertation Committee (Pharmaceutics), Mr. T Obied

07/2007-04/2008 PhD Dissertation Committee (Pharmaceutics), Mr. Lokesh Jain

07/2006-04/2007 MS Dissertation Committee (Biostatistics), Mr. Bassam Dahman

07/2004-04/2009 PhD Dissertation Committee (Epidemiology), Dr. Gayathri Shridhar

07/2004-04/2007 PhD Dissertation Committee (Pharmaceutics), Mr. Tanyifor M Tohnya

07/2004-04/2005 MS Dissertation Committee (Biostatistics), Ms. Sharon Yeats

07/2002-04/2005 PhD Dissertation Committee (Pharmaceutics), Mr. Nehal Lakhani

07/2002-06/2004 MS Dissertation Committee (Biostatistics), Ms. Teresa Eller

07/1999-06/2001 PhD Dissertation Committee (Biostatistics), Ms.Theresa Crofts

07/1999-04/2000 PhD Dissertation Committee (Biostatistics), Ms. Margaret Shih

07/1999-04/2000 PhD Dissertation Committee (Chemistry), Ms. Tracey MacGregor

04/1999-07/1999 MS Masters Dissertation Committee (Pharmaceutics), Mr. Matthew Lee

07/1997-04/2001 PhD Dissertation Committee (Pharmaceutics), Ms. Michelle Rudek

07/1995-06/1997 MS Dissertation Committee (Chemistry), Ms. Leigh Eckel

07/1993-04/1993 PhD Dissertation Committee (Cellular and Molecular Biology), Mr. Andrew Johnson

06/1992-07/1993 MS Dissertation Committee (Pharmacology), Mr. Philip Wu

07/1989-12/1989 PhD Dissertation Committee (Pharmacology), Ms. Wendy Schmidt

**Resident Mentees**

07/2021-12/2022 Zachary Harvanek, MD

**Fellow Mentees**

07/1998-06/1999 Heather Ambrose, MD

07/2009-06/2010 Andrew Poklepovic, MD

07/2015-06/2018 Susanna Curtis, MD

**Faculty Mentees**

07/2002-06/2003, James Khatcheressian, MD

07/2009-06/2012, Beata Holkova, MD

07/2010-06/2012, Prithvi Bose, MD

07/2010-06/2012, Andrew Poklepovic, MD

08/2021-04/2022 Cecelia Calhoun, MD, MPHS, MPA

**NIH/NCI Peer Review**

05/2015 Special Emphasis Panel, NCI Loan Repayment Program

03/2015 Special Emphasis Panel, NCI Clinical Oncology Research Program

08/2014Special Emphasis Panel, New Therapeutic Uses (Pre-application)04/2014 Special Emphasis Panel, NCI Clinical Oncology Research Program05/2013 Special Emphasis Panel, NCI Loan Repayment Program

07/2008-06/2012 Clinical Oncology Study Section  
03/2012 Special Emphasis Panel, Provocative Questions

06/2008 Special Emphasis Panel, Adult Brain Tumor Clinical Consortium

02/2008 Ad Hoc, Clinical Oncology Study Section

05/2008 Special Emphasis Panel, Clinical Oncology

0320/07 Special Emphasis Panel, Clinical Oncology

02/2004 Cancer Center Support Grant Review

07/2003 Special Emphasis Panel, Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults

04/2003 Special Emphasis Panel, Cancer Epidemiology, Prevention, and Control

03/2003 Special Emphasis Panel, Cancer Epidemiology, Prevention, and Control

06/2002 Special Emphasis Panel, Early Clinical Trials on New Anti-Cancer Agents with Phase I Emphasis

04/1997 Special Emphasis Panel, NIDR, Oral Cancer Research Centers

04/1995 Special Emphasis Panel, Clinical Investigations

01/1995-12/1995 PDQ

10/1994 Cancer Center Support Grant Review

**Other Peer Review**

2013 Yale Cancer Center Pilot Project Program

2013 VCU Massey Cancer Center Multi-Investigator Pilot Project Program

1997 Cancer Research UK

1997 AICR Scientific Committee, Italy

**NIH-Sponsored Cooperative Group Committees**

Alliance (formerly CALGB, NCCCTG, ACOSOG)

11/2011-05/2012 Genitourinary

11/2011-05/2012 Health Disparities

11/2011-05/2012 Experimental Therapeutics

11/2011-05/2012 Symptom Intervention

11/2011-05/2012 CCOP

Cancer and Leukemia Group B

06/1995-06/2011 CCOP

06/2008-06/2011 Pharmacology and Experimental Therapeutics

11/2007-06/2011 Genitourinary

11/1999-11/2006 Melanoma Working Group

11/1998-06/2001 Patient Issues

MD Anderson Clinical Oncology Research Base

08/1995-05/1996 Pain Initiative

07/1994-06/1996 Community Oncology Program Steering Committee

**Professional Organization Service**

American Society of Clinical Oncology

10/2008-09/2011 Health Disparities Advisory Working Group

10/2008-09/2011 Liaison, Cancer Prevention Committee

American Society for Hematology

06/2017-12/2019 Sickle Cell Disease Work Group on Health Care Professional Education and Training

12/2017-5/2021 Co-Founder and Co-Director, Adult Sickle Cell Centers Annual Workshops

12/2019-5/2022 Founder and Chair, Ad Hoc Working Group, Training non-hematologists to care for adults living with sickle cell disease

**Other National Service**

Moffitt Cancer Center

07/2011-05/2016 Data Monitoring Committee

National Comprehensive Cancer Network (NCCN)

05/2014-05/2015IRB Director’s Task Force

Sickle Cell Disease Association of America

04/2019-06/2022 Medical and Research Advisory Committee (MARAC)

**Sickle Cell Program Consultation**

10/2014- Community Health Network of CT

1/2024-6/2024 Inova Health Systems

12/2013-4/2022 YNHHS Bridgeport Hospital, Bridgeport CT

10/2016-4/2022 YNHH Lawrence & Memorial Hospital, New London CT

3/9/2018 VCU Health System, Richmond VA

10/17/2108 Westchester Medical Center, Valhalla NY

10/11/2016 Tufts University, Boston MA

06/12/2014 Doctors Community Hospital, Lanham MD

**Peer Review**

Biochemica et Biophysica Acta

Biochemistry

Cancer

Cancer Chemotherapy Pharmacology

Cancer Letters

Cancer Research

Chemico-Biological Interactions

Foundation for Sickle Cell Disease Research

Investigational New Drug

Journal of the National Cancer Institute

Journal of Clinical Oncology

Melanoma Research

NEJM Catalyst

Pediatrics

The Oncologist

Transfusion

**Bibliography:**

See NCBI My Bibliography:

<https://www.ncbi.nlm.nih.gov/sites/myncbi/1pKe0XKZegH/bibliography/40540110/public/?sort=date&direction=ascending>

Peer Reviewed

1. **Roberts, J.D**., Hacker, M.P., Newman, R.A., McCormack,J.J., and Krakoff, I.H. Efficacy and toxicity of 4‑(2‑sulfonatoethylthio)‑cyclophosphamide cyclohexylamine salt (Asta Z‑7557) after intraperitoneal administration to mice. Investigational New Drugs 2:215‑220, 1984.

2. **Roberts, J.D**., Ershler, W.B., Tindle, B.H., and Stewart, J.A. Low dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia. Cancer 56:1001‑1005, 1985.

3. **Roberts, J.D.,** Newman, R.A., Kimberly, P.H.,Hacker, M.P. Regional fibrosis after intraperitoneal administration of mafosfamide. Investigational New Drugs 4:61‑65, 1986.

4. **Roberts, J.D**., Tong, W., Hartshorn, J., Hacker, M.P. Metabolism of Tiazofurin by Human Mononuclear Blood Cells and Erythrocytes in vitro. Cancer Letters, 32:193-197, 1986.

5. **Roberts, J.D.**, Stewart, J.A., McCormack, J.J.,Krakoff, I.H., Culham, C.A., Hartshorn, J.N., Newman, R.A., Haugh, L.A., Young, J.A. Phase I trial of tiazofurin administered by intravenous bolus daily for five days with pharmacokinetic evaluation. Cancer Treatment Reports 71:141-149, 1987.

6. Stewart, J.A., McCormack, J.J., Tong, W., Low, J.B., **Roberts, J.D.** et al. Phase I clinical study of trimetrexate using a daily x 5 schedule. Cancer Research 48:5029-5035, 1988.

7. **Roberts, J.D**., Schmidt, W.J., Tong, W.P., Hacker, M.P. Water Soluble DACH-Pt(II) Complexes: Problems of purification; stability of complexes with nitrogen-containing ligands. Inorganica Chimica Acta 153:2,123-127, 1988.

8. Taylor, R., Tandan, R., **Roberts J**., DiCostanzo, D.P., Sharma, K., Fries, T. Disseminated thymoma and myasthenia gravis: dramatic response to prednisone. Annals of Neurology, 25:208-209, 1989.

9. Colletti, R.B., **Roberts, J.D**., Devlin, J.T., Copeland, K.C. Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Research 49:1882-1884, 1989.

10. **Roberts, J.D.**, Tindle, B.H., MacPherson, B.R. Prolymphocytic transformation of chronic lymphocytic leukemia: a case report of lengthy survival after intensive chemotherapy. American Journal of Hematology 31:131-132, 1989.

11. **Roberts, J.D**., Van Houten, B., Yun Qu, Farrell, N.P. Interactions of novel bis(platinum) complexes with DNA. Nucleic Acids Research 17:9719-9733, 1989.

12. Tandan, R., Taylor, R., DiCostanzo, D.P., Sharma, K., Fries, T., **Roberts, J.D.** Metastasizing thymoma and myasthenia gravis: favorable response to glucocorticoids after failed chemotherapy and radiotherapy. Cancer, 65:1286-1290, 1990.

13. Stewart, J.A., Belinson, J.L., Moore, A.L. Dorighi, J.A., Grant, B.W., Haugh, L.D., **Roberts, J.D**., Albertini, R.J., Branda, R.F. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Research, 50:6302-6310, 1990.

14. Farrell, N., **Roberts, J.D.,** Hacker, M.P. Shikimic acid complexes of platinum. Preparation, reactivity, and antitumor activity of (r,r-1,2-diaminocyclohexane) bis(shikimato)platinum(II). Evidence for a Novel rearrangement involving platinum-carbon bond formation. Journal of Inorganic Biochemistry, 42:237-246, 1991.

15. Colletti, R.B., Copeland, K.C., Devlin, J.T., **Roberts,J.D**., McAuliffe, T.L. Effect of obesity on plasma insulin-like growth factor-I in cancer patients. International Journal of Obesity 15:523-527, 1991.

16. Stewart, J.A., Low, J.B., **Roberts, J.D**., Blow, A. Phase I clinical trial of didemnin B. Cancer 68:2550-2554, 1991.

17. Farrell, N., Kelland,L.R., **Roberts, J.D**., Van Beusichem, M. Activation of the trans geometry in platinum antitumor complexes. A survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Research 52:5065-5072, 1992.

18. Huot, A., Moore, A.L., **Roberts, J.D.,** Hacker, M.P. Nitric oxide modulates lymphocyte proliferation but not secretion of IL-2. Immunol Invest 22:319-327, 1993.

19. **Roberts, J.D**., Bigelow, J.C., Moore, A.L., Belinson, J.L., Stewart, J.A., Hacker, M.P. Increased systemic, but not regional, neopterin production following intraperitoneal administration of interleukin-2 and lack of effect of pterins in the lymphokine-activated killer cell phenomenon. J Immunother 15:53-58, 1994.

20. Farrell, N., Appleton, T.G., Qu, Y., **Roberts, J.D.,** Fontes, S.A., Skov, K.A., Wu, P., and Zou, Y. Effects of geometric isomerism and ligand substitution in bifunctional dinuclear platinum complexes on binding properties and conformation changes in DNA. Biochemistry 34:15480-15486, 1995.

21. Bear, H.D., McFadden, A.W.J, Kostuchenko,P.J., Lipshy, K.A., Hamad,G.G., Turner A.J., **Roberts,J.D.,** Carr, M., Carr,S., and Grant, .S. Bryostatin 1 activates splenic lymphocytes and induces sustained depletion of splenocyte protein kinase C activity in vivo after a single intravenous administration. Anticancer Drugs 7: 299-306, 1996.

22. Bierbach, U., Hambley, T.W., **Roberts, J.D.,** and Farrell, N. Oxidative addition of the dithiobis(formadinium) cation to platinum (II) chloro Am(m)ine compounds: Studies on structure, spectroscopic properties, reactivity and cytotoxicity of a new class of Pt(IV) complexes exhibiting S-thiourea coordination. Inorg. Chem. 35:4865, 1996.

23. Grant, S., **Roberts, J.,** Poplin, E., Tombes, M. B., Kyle, B., Welch, D., Carr, M., and Bear, H. B. Phase IB trial of bryostatin 1 in patients with refractory malignancies. Clinical Cancer Research 4:611-618, 1998.

24. Poplin, E., **Roberts, J**., Tombes, M.B., Grant, S., and Rubin, E. Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study, Investigational New Drugs 17:57-62, 1999.

1. Farthing D, Sica D, Abernathy C, Fakhry I, **Roberts JD,** Abraham, DJ, Swerdlow P. High-performance liquid chromatographic method for determination of vanillin and vanillic acid in human plasma, red blood cells, and urine. J of Chromatography B 726:303-307, 1999.
2. **Roberts JD**, Peroutka J, Beggiolin G, Manzotti C, Piazzoni L, Farrell N. Comparison of cytotoxicity and cellular accumulation of polynuclear platinum complexes in L1210 murine leukemia cell lines. J Inorg Biochem 77:47-50, 1999.
3. **Roberts JD**, Peroutka J, Farrell N. Cellular pharmacology of polynuclear platinum anti-cancer agents. J Inorgan Biochem 77:51-57, 1999.
4. Huan SD, Natale RB, Stewart DJ, Sartiano GP, Stella PJ, **Roberts JD**, Symes AL, Finizio M. A multicenter phase II trial of losoxantrone (DUP-941) in hormone-refractory metastatic prostate cancer. Clin Cancer Res 6: 1333-1336, 2000.
5. McLeod HL, Cassidy J, Powrie RH, Priest DG, Zorbas MA, Synold TW, Shibata S, Spicer D, Bissett D, Pithavala YK, Collier MA, Paradiso LJ, **Roberts JD**. Pharmacokinetic and pharmacodynamic evaluation of the GARFT inhibitor AG2034, Clin Cancer Res 6: 2677-2684, 2000.
6. **Roberts JD,** Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant SG, Synold T, Moran R. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol 45: 103-110, 2000.
7. **Roberts JD**, Shibata S, Spicer DV, McLeod HL, Tombes MB, Kyle B, Carroll M, Sheedy B, Collier MA, Pithavala YK, Paradiso L, Clendeninn NJ. Phase I study of AG2034, a targeted GARFT inhibitor, administered once every 3 weeks. Cancer Chemother Pharmacol 45: 423-427, 2000.
8. Kavanagh BD, Khandelwal SR, Schmidt-Ullrich RK, **Roberts JD**, PearlmanAD, Shaw EG, Venitz J, Dusenbery KE, Abraham DJ, Gerber MJ. A phase I study of RSR13, radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics. Int J Radiat Oncol Biol Phys. 49(4):1133-1139, 2001.
9. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, **Roberts JD**, Krag DN. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. Arterioscler Thromb Vasc Biol 21(2):255-61, 2001.
10. Bear HD, **Roberts JD**, Cornell D, Tombes MB, Kyle B. Adoptive immunotherapy of cancer with pharmacologically activated lymph node lymphocytes: A pilot clinical trial. Cancer Immunol Immunoth,50:269-274, 2001.
11. Hegmans A, Qu Y, Kelland LR, **Roberts JD**, Farrell N. Novel approaches to polynuclear platinum pro-drugs. Selective release of cytotoxic platinum-spermidine species through hyrolytic cleavage of carbamates. Inorg Chem 40:6108-6114, 2001.

38. **Roberts JD**, Smith MR, Feldman EJ, Cragg L, Grant S. Phase I Study of Bryostatin-1 and Fludarabine in Patients with Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin's Lymphoma. Clin Lymphoma 3:184-188, 2002.

39. Cragg LH, Andreeff M, Feldman E, **Roberts J**, Murgo A, Winning M, Tombes MB, Roboz G, Kramer L, Grant S. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia. Clin Cancer Res. 8:2123-2133, 2002.

1. Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, **Roberts JD**, Krag DN. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. Br J Haematol. 120:109-116, 2003.
2. McClish DK, **Roberts JD**. Phase I studies of weekly administration of cytotoxic agents: Implications of a mathematical model. Investigational New Drug 21: 299-308, 2003.
3. Hagan MP, Winter KA, Kaufman DS, Wajsman Z, Zietman AL, Heney NM, Toonkel LM, Jones CU, **Roberts JD**, Shipley WU. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 57: 665-672, 2003.

43. Levine, EG, Halabi S, **Roberts JD,** Kaplan EB, Rago R, Atkins JN, Vogelzang NJ. Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma. Cancer 94:665-672, 2003.

44. Smith, WR, Bovbjeg, VE, Penberthy, LT, McClish, DK, Levenson, JL, **Roberts, JD**, Gil, K, Roseff, SD, Aisiku, IP. [Understanding pain and improving management  
of sickle cell disease: the PiSCES Study](http://www.nmanet.org/OC183.pdf). Journal of the National Medical Association 97: 183-193, 2005.

45. McClish DK, Penberthy LT, Bovbjerg VE, **Roberts JD,** Aisiku IP, Levenson JL, Roseff SD, Smith WR. Health related quality of life in sickle cell patients: the PiSCES project. Health Qual Life Outcomes 29:50, 2005.

46. [Hawkins W, Mitchell C, McKinstry R, Gilfor D, Starkey J, Dai Y, Dawson K, Ramakrishnan V, **Roberts JD**, Yacoub A, Grant S, Dent P.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16319524&query_hl=1&itool=pubmed_docsum) Transient Exposure of Mammary Tumors to PD184352 and UCN-01 Causes Tumor Cell Death In Vivo and Prolonged Suppression of Tumor Regrowth. Cancer Biol Ther 4:1275-1284, 2005.

47. McClish DK, Levenson JL, Penberthy LT, Roseff SD, Bovbjerg VE, **Roberts JD,** Aisiku IP, Smith WR, Gender differences in pain and health care utilization for adult sickle cell patients: the PiSCES project. Journal of Women’s Health. 2006; 15: 146-154.

48. Smith TJ, Coyne PJ, Smith WR, **Roberts JD**, Smith V. Use of an implantable drug delivery system for refractory chronic sickle cell pain.Am J Hematol. 2005 Feb;78(2):153-4.

49. [**Roberts JD**, Niedzwiecki D, Carson WE, Chapman PB, Gajewski TF, Ernstoff MS, Hodi FS, Shea C, Leong SP, Johnson J, Zhang D, Houghton A, Haluska FG; for the Cancer and Leukemia Group B.](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16365605&itool=pubmed_DocSum) Phase 2 Study of the g209-2M melanoma peptide vaccine and low-dose interleukin-2 in advanced melanoma: Cancer and Leukemia Group B 509901. J Immunother. 29:95-101, 2006.

50. **Roberts JD**, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol. 530:54-58, 2006.

51. **Roberts JD**, Smith MR, Feldman EJ, Cragg L, Millenson MM, Roboz GJ, Honeycutt C, Thune R, Padavic-Shaller K, Carter WH, Ramakrishnan V, Murgo AJ, Grant S. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma. Clin Cancer Res. 12: 5809-16, 2006.

52. Yacoub A, Hawkins W, Hanna D, Young H, Park MA, Grant M, **Roberts JD**, Curiel DT, Fisher PB, Valerie K, Grant S, Hagan MP, Dent P. Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment. Mol Pharmacol 71:259-75, 2007.

53. Mitchell C, Kabolizadeh P, Ryan J, **Roberts JD**, Yacoub A, Curiel DT, Fisher PB, Hagan MP, Farrell NP, Grant S, Dent P. Low-dose BBR3610 toxicity in colon cancer cells is p53-independent and enhanced by inhibition of epidermal growth factor receptor (ERBB1)-phosphatidyl inositol 3 kinase signaling. Mol Pharmacol. 2007 Sep;72(3):704-14.

54. Aisiku IP, Penberthy LT, Smith WR, Bovbjerg VE, McClish DK, Levenson JL, **Roberts JD**, Roseff SD. Patient satisfaction in specialized versus nonspecialized adult sickle cell care centers: the PiSCES study. J Natl Med Assoc. 2007 Aug;99(8):886-90.

56. Mitchell C, Park MA, Zhang G, Yacoub A, Curiel DT, Fisher PB, **Roberts JD**, Grant S, Dent P. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells. Mol Cancer Ther. 2007 Dec;6(12):3101-12.

57. Levenson JL, McClish DK, Dahman BA, Bovbjerg VE, Citero VD, Penberthy LT, Aisiku IP, **Roberts JD**, Roseff SD, Smith WR. Depression and anxiety in adults with sickle cell disease: The PiSCES Project. Psychosom Med. 2007 Dec 70(2):192-6.

58. Smith WR, Penberthy LT, Bovbjerg VE, McClish DK, **Roberts JD**, Dahman B, Aisiku IP, Levenson JL, Roseff SD. Daily assessment of pain in adults with sickle cell disease. Ann Intern Med. 2008 Jan 15;148(2):94-101.

59. Zhang G, Park MA Mitchell C, Hamed H, Rahmani M, Martin AP, Curiel DT, Yacoub A, Graf M, Lee R, **Roberts JD**, Fisher PB, Grant S, Dent P. Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res 14:5385-99, 2008.

60. Hamed H, Hawkins W, Mitchell C, Gilfor D, Zhang G, Pei XY, Dai Y, Hagan MP, **Roberts JD,** Yacoub A, Grant S, Dent P. Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo. Mol Cancer Ther 7:616-29, 2008.

61. Langer C, Radmacher MD, Ruppert AS, Whitman SP, Paschka P, Mrózek K, Baldus CD, Vukosavljevic T, Liu CG, Ross ME, Powell BL, de la Chapelle A, Kolitz JE, Larson RA, Marcucci G, Bloomfield CD; Cancer and Leukemia Group B (CALGB). Collaborators: Bloomfield CD, Theil KS, Minka D, Heerema NA, Hurd DD, Flejter WL, Pettenati MJ, Budman DR, Koduru PR, Levine EG, Block AW, Clamon GH, Patil SR, Walsh WW, Jaswaney V, Mitchell MJ, Miron P, Crawford J, Qumsiyeh MB, Bartlett NL, Watson MS, Garcia-Heras J, Muss HB, Allen EF, Tang M, Segal HM, Beauregard LJ, Winer EP, Tantravahi R, Dal Cin P, Morton CC, Leonard J, Koduru PR, Carroll AJ, Mathew S, Ernstoff MS, Mohandas TK, Clark JW, Dal Cin P, Morton CC, Silverman LR, Najfeld V, Nattam S, Bader PI, Pacheco EI, Morton CC, Dal Cin P, Atkins LL, Grubbs SS, Borgaonkar DS, Meck JM, Parker BA, Dell'Aquila ML, Shea T, Rao KW, Shadduck RK, Diggans GR, Ellerton J, Bernstein R, Dell'Aquila ML, **Roberts JD**, Jackson-Cook C, Perry MC, Huang TH, Fleming G, Roulston D, Le Beau MM, Peace DJ, McCorquodale MM, Graziano SL, Stein CK, Sikov W, Meloni-Ehrig A, Morrison VA, Tharapel SA, Liu MC, Meck JM, Rai KR, Koduru PR, Peterson BA, Hirsch BA, Green MR, Pai GS, Ryan CJ, Richkind KE, Reid T, Borgaonkar DS. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008 Jun 1;111(11):5371-9. doi: 10.1182/blood-2007-11-124958. Epub 2008

Mar 31.

62. Farmer MN, Raddin RS, **Roberts JD.** The relationship between taste, olfaction, and nutrition in the cancer population. J Supportive Onco 2009 Mar/Apr;7(2):70-72.

63. McClish DK, Smith WR, Dahman BA, Levenson JL, **Roberts JD**, Penberthy LT, Aisiku

IP, Roseff SD, Bovbjerg VE. Pain site frequency and location in sickle cell disease: the PiSCES project. Pain. 2009 Sep;145(1-2):246-51. doi:10.1016/j.pain.2009.06.029. Epub 2009 Jul 23. PubMed PMID: 19631468; PubMed Central PMCID: PMC2771372.

64. Aisiku IP, Smith WR, McClish DK, Levenson JL, Penberthy LT, Roseff SD, Bovbjerg VE, **Roberts JD**. Comparisons of high versus low emergency department utilizers in sickle cell disease. Ann Emerg Med. 2009 May;53(5):587-93. doi:10.1016/j.annemergmed.2008.07.050. Epub 2008 Oct 16. PubMed PMID: 18926599.

65. Sridhar G, Masho SW, Adera T, Ramakrishnan V, **Roberts JD**. Do African American men have lower survival from prostate cancer compared with white men? A meta-analysis. Am J Mens Health. 2010 Sep;4(3):189-206. doi: 10.1177/1557988309353934. Epub 2010 May 18.

66. Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons M, Hogan K, Roodman D, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD, Kolla SS, Doyle L, Wright JJ, Sullivan DM, **Roberts JD,** Grant S. Phase I Trial of Bortezomib (PS-341; NSC 681239) and Alvocidib (Flavopiridol; NSC 649890) in Patients with Recurrent or Refractory B-cell Neoplasms. Clin Cancer Res. 2011 May 15:17(10):3388-97.

67. Dickson MA, Rathkopf DE, Carvajal RD, Grant S, **Roberts JD**, Reid JM, Ames MM, McGovern RM, Lefkowitz RA, Gonen M, Cane LM, Dials HJ, Schwartz GK. A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Invest New Drugs. 2011 Oct;29(5):1004-12. Epub 2010 May 12. PubMed PMID: 20461440.

68. **Roberts JD**, Ramakrishnan V. Phase II trials powered to detect tumor subtypes. Clin Cancer Res. 2011 Sep 1;17(17):5538-45. PubMed PMID:21737510.

69. Bose P, Perkins EB, Honeycutt C, Wellons MD, Stefan T, Jaccobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Figg WD, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, **Roberts, JD**, Grant S. Phase I trial of the combination of flavopiridol and imatinib in patients with Bcr-Abl+ hematological malignancies. Cancer Chemother Pharmacol 2012 Jun;69(6):1657-67. PMID: 22349810; PMC3365614.

70. Poklepovic A, Youssefian LE, Winning M, Birdsell CA, Crosby NA, Ramakrishnan V, Ernstoff MS, **Roberts JD**. Phase I trial of bortezomib and dacarbazine in melanoma and soft tissue sarcoma. Invest New Drugs. 2013 Aug;31(4):937-42. doi:10.1007/s10637-012-9913-8. Epub 2013 Jan 13. Erratum in: Invest New Drugs. 2013 Aug;31(4):1095. Youseffian, Leena [corrected to Youssefian, Leena E]. PubMed PMID: 23315028; PubMed Central PMCID: PMC3844155.

71. Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM, Kmieciak M, Shrader E, Wellons MD, Sankala H, Doyle A, Wright J, **Roberts JD**, Grant S. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res. 2013 Apr 1;19(7):1873-83. PMID: 23515411; PMC3618599.

72. Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, **Roberts JD**, Sullivan D, Grant S. Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms. Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23. PubMed PMID: 25248382; PubMed Central PMCID: PMC4233160.

73. Smith WR, McClish DK, Dahman BA, Levenson JL, Aisiku IP, Citero VD, Bovbjerg VE, **Roberts JD**, Penberthy LT, Roseff SD. Daily Home Opioid Use in Adults with Sickle Cell Disease: the PiSCES Project. Journal of Opioid Management. 2015 May-Jun;11(3):243-53.

74. Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, **Roberts JD**, Vokes EE, Cohen EE. [Phase II Trial of Dasatinib for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and for Non-Adenoid Cystic Malignant Salivary Tumors.](http://www.ncbi.nlm.nih.gov/pubmed/26598548) Ann Oncol. 2015 Nov 23. pii: mdv537. [Epub ahead of print] PubMed PMID: 26598548.

75. **Roberts JD**, Carter LC, Smith WR. [RE: Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease.](http://www.bloodjournal.org/content/126/20/2320.e-letters#re-hypoxia-reperfusion-affects-osteogenic-lineage-and-promotes-sickle-cell-bone-disease) Blood eLetter 1 Jan 2016.

76. Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, **Roberts JD**, Sullivan D, Landgren O, Grant S. [A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.](https://www.ncbi.nlm.nih.gov/pubmed/26446942) Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7. PubMed PMID: 26446942; PubMed Central PMCID: PMC4775365.

77. Soliman HH, Minton SE, Han HS, Ismail-Khan R, Neuger A, Khambati F, Noyes D, Lush R, Chiappori AA, **Roberts JD**, Link C, Vahanian NN, Mautino M, Streicher H, Sullivan DM, Antonia SJ. [A phase I study of indoximod in patients with advanced malignancies.](https://www.ncbi.nlm.nih.gov/pubmed/27008709) Oncotarget. 2016 Apr 19;7(16):22928-38. doi: 10.18632/oncotarget.8216. PubMed PMID: 27008709; PubMed Central PMCID: PMC5008412.

78. Poklepovic A, Gordon S, Shafer DA, **Roberts JD**, Bose P, Geyer CE Jr, McGuire WP, Tombes MB, Shrader E, Strickler K, Quigley M, Wan W, Kmieciak M, Massey HD, Booth L, Moran RG, Dent P. [Phase I study of pemetrexed with sorafenib in advanced solid tumors.](https://www.ncbi.nlm.nih.gov/pubmed/27213589) Oncotarget. 2016 Jul 5;7(27):42625-42638. doi: 10.18632/oncotarget.9434. PubMed PMID: 27213589; PubMed Central PMCID: PMC5173162.

79. Himelstein AL, Foster J, Khatcheressian JL, **Roberts JD**, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425.

80. Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, Shea T, Ruan J, Parekh S, Strair R, Flowers C, Morgan D, Kmieciak M, Bose P, Kimball A, Badros AZ, Baz R, Lin HY, Zhao X, Reich RR, Tombes MB, Shrader E, Sankala H, **Roberts JD**, Sullivan D, Grant S, Holkova B. [A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma.](https://www.ncbi.nlm.nih.gov/pubmed/30122201/)Clin Lymphoma Myeloma Leuk. 2018 Sep;18(9):569-575.e1. doi: 10.1016/j.clml.2018.05.023. Epub 2018 Jun 6. PubMed PMID: 30122201.

81. Holkova B, Yazbeck V, Kmieciak M, Bose P, Ma S, Kimball A, Tombes MB, Shrader E, Wan W, Weir-Wiggins C, Singh A, Hogan KT, Conine S, Sankala H, **Roberts JD**, Shea TC, Grant S. [A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma.](https://www.ncbi.nlm.nih.gov/pubmed/28103725) Leuk Lymphoma. 2017 Jun;58(6):1349-1357. doi: 10.1080/10428194.2016.1276287. Epub 2017 Jan 19. PubMed PMID: 28103725.

82. McClish DK, Smith WR, Levenson JL, Aisiku IP, **Roberts JD**, Roseff SD, Bovbjerg VE. Comorbidity, Pain, Utilization and Psychosocial Outcomes in Older versus Younger Sickle Cell Adults: the PiSCES Project. Biomed Research International. 2017, Article ID 4070547. doi:10.1155/2017/4070547

83. **Roberts JD**, Spodick J, Cole J, Bozzo J, Curtis S, Forray A. [Marijuana Use in Adults Living with Sickle Cell Disease.](https://www.ncbi.nlm.nih.gov/pubmed/30014039/) Cannabis Cannabinoid Res. 2018;3(1):162-165. doi: 10.1089/can.2018.0001. eCollection 2018. PubMed PMID: 30014039; PubMed Central PMCID: PMC6044416.

84. Smith WR, McClish DK, Levenson J, Aisiku I, Dahman B, Bovbjerg VE, Roseff S, **Roberts J.** [Predictive Ability of Intermittent Daily Sickle Cell Pain Assessment: The PiSCES Project.](https://www.ncbi.nlm.nih.gov/pubmed/29036363/)Pain Med. 2018 Oct 1;19(10):1972-1981. doi: 10.1093/pm/pnx214. PubMed PMID: 29036363; PubMed Central PMCID: PMC6176749.

85. Gordon SW, McGuire WP 3rd, Shafer DA, Sterling RK, Lee HM, Matherly SC(3), **Roberts JD**, Bose P, Tombes MB, Shrader EE, Ryan AA, Kmieciak M, Nguyen T, Deng X, Bandyopadhyay D, Dent P , Poklepovic AS. Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma. Am J Clin Oncol. 2019 Jul 11. doi: 10.1097/COC.0000000000000567. [Epub ahead of print]

86. Balbuena-Merle R, Curtis SA, Devine L, Gibb DR, Karafin MS, Luckey CJ, Tormey CA, Siddon AJ, **Roberts JD**, Hendrickson JE. Red blood cell alloimmunization is associated with lower expression of FcγR1 on monocyte subsets in patients with sickle cell disease.Transfusion. 2019 Jul 29. doi: 10.1111/trf.15463. [Epub ahead of print]

87. Smith WR, McClish DK, **Roberts JD**, Kandalaft O, Dahman B, Knisely J, Levenson J, Roseff S, Aisiku IP. Prescription Opioid Misuse Index in sickle cell patients: A brief questionnaire

to assess at-risk for opioid abuse. J Opioid Manag. 2019 Jul/Aug;15(4):323-331. doi: 10.5055/jom.2019.0517.

88. Koch CD, Xu L, Curtis SA, **Roberts JD**, Bunch DR, El-Khoury JM. [Urinary cannabinoid mass spectrometry profiles differentiate dronabinol from cannabis use.](https://www.ncbi.nlm.nih.gov/pubmed/32795544/)Clin Chim Acta. 2020 Nov;510:515-521. doi: 10.1016/j.cca.2020.08.014. Epub 2020 Aug 12. PubMed PMID: 32795544.

89. Curtis SA, Lew D, Spodick J, Hendrickson JE, Minniti CP, **Roberts JD**. Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Adv. 2020 Aug 25;4(16):3814-3821. doi10.1182/bloodadvances.2020002325. PMID: 32790846.

90. Kanter J, Smith WR, Desai PC, Treadwell M, Andemariam B, Little J, Nugent D, Claster S, Manwani DG, Baker J, Strouse JJ, Osunkwo I, Stewart RW, King A, Shook LM, **Roberts JD**, Lanzkron S. Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects. Blood Adv. 2020 Aug 25;4(16):3804-3813. doi: 10.1182/bloodadvances.2020001743. PMID: 32785684.

91. Rousseau R, Weisberg DF, Gorero J, Parwani V, Bozzo J, Kenyon K, Smith C, Cole J, Curtis S, Forray A, **Roberts JD**. Utilization, financial outcomes and stakeholder perspectives of a re-organized adult sickle cell program. PLoS One. 2020 Jul 24;15(7):e0236360. doi: 10.1371/journal.pone.0236360. eCollection 2020. PMID: 32706825

92. Curtis SA, Brandow AM, DeVeaux M, Zeltermam D, Devine L, **Roberts JD**. [Daily Cannabis Users with Sickle Cell Disease Show Fewer Admissions than Others with Similar Pain Complaints.](https://www.ncbi.nlm.nih.gov/pubmed/32923662/)Cannabis Cannabinoid Res.

2020;5(3):255-262. doi: 10.1089/can.2019.0036. eCollection 2020. PubMed PMID: 32923662; PubMed Central PMCID: PMC7480712.

93. Curtis SA, Raisa BM, **Roberts JD**, Hendrickson JE, Starrels J, Lesley D, Michelle D, Daniel Z, Brandow AM. Non-crisis related pain occurs in adult patients with sickle cell disease despite chronic red blood cell exchange transfusion therapy. Transfus Apher Sci. 2022 Apr;61(2):103304. doi: 10.1016/j.transci.2021.103304. Epub 2021 Oct 30. PMID: 34782244.

94. **Roberts, JD**. Letter to the Editor: Surgery or Endovascular Therapy for Chronic Limb Ischemia N Engl J Med 2023; 388:e37. DOI: 10.1056/NEJMc2300713.

95. Fouda RT, Cherukury HM, Kiven SB, Garcia NR, Argueta DA, Velasco GJ, Gupta K, **Roberts JD**. Colchicine reduces inflammation in a humanized transgenic murine model of sickle cell disease. Haematologica. 2023 Aug 3. doi: 10.3324/haematol.2023.283377. Epub ahead of print. PMID: 37534545.

Other Publications

1. Hacker MP, **Roberts JD**. Cisplatin Efficacy and Toxicity:Are they Separable?, in Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy.eds. Nicolini M and Bandoli G, Martinus Nijhoff Publishing, Boston, 1988.

1. **Roberts, JD**, Moore AL, Hacker MP, Huot AE. Mechanism of Interleukin-2 Induced Hypotension in Humans: Activation of the Nitric Oxide/Cyclic GMP Pathway. In The Biology of Nitric Oxide (Proceedings of the Second International Meeting on the Biology of Nitric Oxide). Eds. Moncada S, Marletta MA, Hibbs JB, Jr, Higgs EA. Colchester, United Kingdom: Portland Press, 1992.
2. Hillner BE, **Roberts, JD**. Role of perspective and other uncertainties in cost-effectiveness assessments in advanced prostate cancer. J Natl Cancer Inst 92: 1704-1706, 2000.
3. Grant S, **Roberts JD.** The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resistance Updates 6:15-26, 2003.
4. **Roberts JD.** E2F1 amplification and genetic heterogeneity in melanoma. Cancer Biol Ther. 5:691-2, 2006.